摘要
目的：探讨玻璃体腔内注射雷珠单抗联合黄斑格栅样光凝治疗糖尿病性黄斑水肿（DME）的临床疗效。方法选择2012年2月至2014年11月 DME 患者52例（68眼），随机分为两组。对照组27例（36眼）行黄斑格栅样光凝，观察组25例（32眼）先行玻璃体腔内注射雷珠单抗，再于注药1周后行黄斑格栅样光凝。观察两组治疗前后患者最佳矫正视力（BCVA）、黄斑中心凹处视网膜厚度（CMT）的变化。结果观察组治疗后 BCVA（0.23±0.17）较术前明显提高，且治疗后观察组视力优于对照组（0.19±0.14），差异有统计学意义（P〈0.05）。两组治疗后 CMT 较治疗前降低，且观察组 CMT 小于对照组[（310.52±49.36）μm 比（389.74±131.62）μm]，差异有统计学意义（P〈0.05）。结论雷珠单抗联合黄斑格栅样光凝治疗糖尿病性黄斑水肿，术后视力恢复更显著，黄斑水肿吸收效果更明显。
Objective To investigate the efficacy ranibizumab combined with photocoagulation on diabetic macular edema（ DME）. Methods From February 2014 to November 2014,52 patients （68 eyes）were selected,and were randomly divided into the two groups,27 cases（36 eyes）in the con-trol group were given macular grid photocoagulation,while 25 cases（32 eyes）in the observation group were first treated with glass cavity injection licensed resistance,and macular grid photocoagulation was performed in one week after injection. The best corrected visual acuity（BCVA）,central macular retinal thickness recess（ CMT）changes before and after three mouths treatment in the two groups were ob-served. Results The BCVA of the observation group（0. 23 ± 0. 17）was significantly improved compared with that before operation,the difference was significant（P〈 0. 05）,and the visual acuity was better than that in the control group（0. 19 ± 0. 14）,the differences were significant（P〈 0. 05）. After treat-ment,the CMT in the two groups was less than that before treatment,and the CMT in the observation group was lower than that in the control group[（310. 52 ± 49. 36）μm vs.（389. 74 ± 131. 62）μm],the difference was significant（ P〈 0. 05）. Conclusions Ranibizumab combined with photocoagulation treatment of diabetic macular edema,postoperative visual acuity was more significant ,macular edema absorption effect is more obvious.
出处
《中国实用医刊》
2016年第22期102-104,共3页
Chinese Journal of Practical Medicine
